-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Bristol-Myers Squibb, Raises Price Target to $65

Benzinga·01/08/2025 11:41:12
Listen to the news
Truist Securities analyst Robyn Karnauskas maintains Bristol-Myers Squibb (NYSE:BMY) with a Buy and raises the price target from $62 to $65.